15 / 30
PRIOR THERAPIES
Cabozantinib
(N=470)
Placebo
(N=237)
Prior systemic anticancer regimens for HCC, %
One prior regimen
71
73
Two prior regimens
28
26
Prior systemic therapy, %
Sorafenib
100
100
Regorafenib
1
1
Lenvatinib
0
<1
Anti-PD-1/PD-L1
3
1
Chemotherapy
9
13
Investigational agents
13
8
Median total duration of prior sorafenib, months
5.3
4.8
Median time from disease progression to rand, months
1.4
1.2
CELESTIAL Phase III study